JP2014218520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014218520A5 JP2014218520A5 JP2014165961A JP2014165961A JP2014218520A5 JP 2014218520 A5 JP2014218520 A5 JP 2014218520A5 JP 2014165961 A JP2014165961 A JP 2014165961A JP 2014165961 A JP2014165961 A JP 2014165961A JP 2014218520 A5 JP2014218520 A5 JP 2014218520A5
- Authority
- JP
- Japan
- Prior art keywords
- amphoteric
- liposome
- charge carrier
- liposome according
- isoelectric point
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 claims description 34
- 239000002800 charge carrier Substances 0.000 claims description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 11
- 150000002632 lipids Chemical class 0.000 claims description 10
- 150000001982 diacylglycerols Chemical class 0.000 claims description 7
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 6
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 5
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 5
- 229940106189 ceramide Drugs 0.000 claims description 5
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 5
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 238000001890 transfection Methods 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000002088 nanocapsule Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 6
- 150000001449 anionic compounds Chemical class 0.000 description 3
- -1 cation compound Chemical class 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- RSMRWWHFJMENJH-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;methyl sulfate Chemical compound COS([O-])(=O)=O.CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC RSMRWWHFJMENJH-LQDDAWAPSA-M 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10109897.9 | 2001-02-21 | ||
| DE10109897A DE10109897A1 (de) | 2001-02-21 | 2001-02-21 | Fakultativ kationische Liposomen und Verwendung dieser |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013237869A Division JP2014031383A (ja) | 2001-02-21 | 2013-11-18 | 両性リポソーム及びその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016001813A Division JP2016104786A (ja) | 2001-02-21 | 2016-01-07 | 両性リポソーム及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014218520A JP2014218520A (ja) | 2014-11-20 |
| JP2014218520A5 true JP2014218520A5 (https=) | 2015-01-08 |
Family
ID=7675950
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002565572A Pending JP2004525898A (ja) | 2001-02-21 | 2002-02-21 | 両性リポソーム及びその使用 |
| JP2010211089A Expired - Fee Related JP5480764B2 (ja) | 2001-02-21 | 2010-09-21 | 両性リポソーム及びその使用 |
| JP2013237869A Pending JP2014031383A (ja) | 2001-02-21 | 2013-11-18 | 両性リポソーム及びその使用 |
| JP2014165961A Pending JP2014218520A (ja) | 2001-02-21 | 2014-08-18 | 両性リポソーム及びその使用 |
| JP2016001813A Pending JP2016104786A (ja) | 2001-02-21 | 2016-01-07 | 両性リポソーム及びその使用 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002565572A Pending JP2004525898A (ja) | 2001-02-21 | 2002-02-21 | 両性リポソーム及びその使用 |
| JP2010211089A Expired - Fee Related JP5480764B2 (ja) | 2001-02-21 | 2010-09-21 | 両性リポソーム及びその使用 |
| JP2013237869A Pending JP2014031383A (ja) | 2001-02-21 | 2013-11-18 | 両性リポソーム及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016001813A Pending JP2016104786A (ja) | 2001-02-21 | 2016-01-07 | 両性リポソーム及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7371404B2 (https=) |
| EP (1) | EP1363601B1 (https=) |
| JP (5) | JP2004525898A (https=) |
| CN (1) | CN1241549C (https=) |
| AT (1) | ATE363893T1 (https=) |
| AU (1) | AU2002234643B2 (https=) |
| BR (1) | BRPI0207775B1 (https=) |
| CA (1) | CA2438116C (https=) |
| DE (2) | DE10109897A1 (https=) |
| ES (1) | ES2289079T3 (https=) |
| WO (1) | WO2002066012A2 (https=) |
Families Citing this family (135)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10109897A1 (de) * | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
| DE10207177A1 (de) * | 2002-02-19 | 2003-09-04 | Novosom Ag | Fakultativ kationische Lipide |
| US7858117B2 (en) * | 2002-02-21 | 2010-12-28 | Novosom Ag | Amphoteric liposomes and their use |
| WO2003093449A2 (en) * | 2002-05-06 | 2003-11-13 | Nucleonics, Inc. | Methods for delivery of nucleic acids |
| US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
| DE10255106A1 (de) * | 2002-11-24 | 2004-06-09 | Novosom Ag | Liposomale Glucocorticoide |
| EP1547580A1 (en) * | 2003-12-23 | 2005-06-29 | MediGene Oncology GmbH | Loading of a camptothecin drug into colloidal nanoparticles |
| DE102004054730A1 (de) | 2004-03-28 | 2006-05-11 | Novosom Ag | Serumstabile amphotere Liposomen |
| US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| EP1807050A1 (en) * | 2004-11-05 | 2007-07-18 | Novosom AG | Improvements in or relating to pharmaceutical compositions comprising an oligonucleotide as an active agent |
| EP1811960A2 (en) * | 2004-11-19 | 2007-08-01 | Novosom AG | Improvements in or relating to pharmaceutical compositions for local administration |
| EP1764090A1 (en) * | 2005-09-15 | 2007-03-21 | Novosom AG | Amphoteric liposomes for local drug applications |
| EP1676569A1 (en) * | 2004-12-30 | 2006-07-05 | Pevion Biotech Ltd. | Lyophilization of virosomes |
| EP1911443A1 (en) * | 2006-10-13 | 2008-04-16 | Novosom AG | Amphoteric liposomes, method of formulating an amphoteric liposome and a method of loading an amphoteric liposome |
| US20120021042A1 (en) * | 2005-09-15 | 2012-01-26 | Steffen Panzner | Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances |
| US20080088046A1 (en) * | 2006-10-13 | 2008-04-17 | Steffen Panzner | Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome |
| EP1764089A1 (en) * | 2005-09-15 | 2007-03-21 | Novosom AG | Serum stable liposomes comprising amphoter II lipid mixtures |
| KR20080082956A (ko) * | 2005-09-15 | 2008-09-12 | 노보솜 아게 | 양쪽성 리포솜의 개선 또는 양쪽성 리포솜에 관련된 개선 |
| US8093369B2 (en) * | 2005-10-11 | 2012-01-10 | Ben Gurion University Of The Negev Research And Development Authority Ltd. | Compositions for silencing the expression of VDAC1 and uses thereof |
| CA2631677C (en) * | 2005-12-01 | 2014-08-12 | Pronai Therapeutics, Inc. | Amphoteric liposome formulation |
| EP1971371B1 (en) | 2005-12-01 | 2015-08-05 | Pronai Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
| HUE029994T2 (en) | 2005-12-08 | 2017-04-28 | Insmed Inc | Lipid-based compositions of antiinfectives for treating pulmonary infections |
| EP3354260B1 (en) * | 2006-04-06 | 2020-12-09 | Insmed Incorporated | Methods for coacervation induced liposomal encapsulation and formulations thereof |
| JP5424885B2 (ja) * | 2006-10-13 | 2014-02-26 | マリーナ バイオテック，インコーポレイテッド | 両性リポソームにおけるまたは両性リポソームに関する改善、両性リポソームを処方する方法および両性リポソームに充填する方法 |
| US20140178462A1 (en) * | 2006-10-13 | 2014-06-26 | Marina Biotech, Inc. | Amphoteric liposomes comprising neutral lipids |
| WO2008074487A2 (en) * | 2006-12-19 | 2008-06-26 | Novosom Ag | Lipids and lipid assemblies comprising transfection enhancer elements |
| DK2308514T3 (da) | 2007-03-23 | 2013-09-02 | To Bbb Holding B V | Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren |
| US20080260895A1 (en) * | 2007-04-17 | 2008-10-23 | Vermeire Drew A | Milk replacer composition and product and method for producing the same |
| CA2686735A1 (en) | 2007-05-04 | 2008-11-13 | Mdrna, Inc. | Amino acid lipids and uses thereof |
| WO2008137717A1 (en) | 2007-05-04 | 2008-11-13 | Transave, Inc. | Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
| DE102007029471A1 (de) | 2007-06-20 | 2008-12-24 | Novosom Ag | Neue fakultativ kationische Sterole |
| EP2170932A4 (en) | 2007-06-20 | 2012-10-10 | Phylogica Ltd | COMPOSITIONS AND APPLICATIONS THEREOF IN THE TREATMENT OF ACUTE ATOMIC SYNDROME (ARDS) AND ASSOCIATED CLINICAL ILLNESSES |
| WO2009031896A2 (en) * | 2007-09-07 | 2009-03-12 | Synvolux Ip B.V. | Improved liposomes and uses thereof |
| CA2702103A1 (en) * | 2007-10-12 | 2009-04-16 | Novosom Ag | Improvements in or relating to amphotaric liposomes comprising neutral lipids |
| CN102112110A (zh) * | 2008-06-06 | 2011-06-29 | 米尔纳医疗股份有限公司 | 用于RNAi试剂体内递送的新型组合物 |
| CN102231979B (zh) * | 2008-10-16 | 2014-10-29 | 玛瑞纳生物技术有限公司 | 基因沉默治疗剂的脂质体有效递送方法和组合物 |
| JP5392707B2 (ja) * | 2009-03-31 | 2014-01-22 | 株式会社Ｎｔｔドコモ | 膜小胞分裂システム |
| WO2010113172A1 (en) * | 2009-03-31 | 2010-10-07 | Council Of Scientific & Industrial Research | Amphoteric liposomal compositions for cellular delivery of small rna molecules for use in rna interference |
| WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
| DK2823810T3 (da) | 2009-07-09 | 2019-05-27 | Novosom Verwaltungs Gmbh | Amfotere liposomer, der omfatter iminolipider |
| ES2386855T3 (es) * | 2009-07-09 | 2012-09-03 | Marina Biotech, Inc. | Emulación de estructuras de lipoproteínas |
| HUE042177T2 (hu) | 2009-12-01 | 2019-06-28 | Translate Bio Inc | Szteroidszármazék mRNS szállítására humán genetikai betegségekben |
| WO2011120023A1 (en) | 2010-03-26 | 2011-09-29 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting survivin gene expression uses thereof |
| WO2011133584A2 (en) | 2010-04-19 | 2011-10-27 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting hras gene expression and uses thereof |
| WO2011139843A2 (en) | 2010-04-28 | 2011-11-10 | Marina Biotech, Inc. | Multi-sirna compositions for reducing gene expression |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| WO2012075040A2 (en) | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
| WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| AU2012260434A1 (en) | 2011-05-23 | 2013-10-31 | Phylogica Limited | Method of determining, identifying or isolating cell-penetrating peptides |
| PL3586861T3 (pl) | 2011-06-08 | 2022-05-23 | Translate Bio, Inc. | Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| CN102532259A (zh) * | 2012-03-09 | 2012-07-04 | 中国药科大学 | 基于寡肽的阳离子脂质衍生物及在药剂制剂中的应用 |
| CN102603866B (zh) * | 2012-03-15 | 2014-01-15 | 中国药科大学 | 基于寡肽的pH敏感型两性离子及其在药剂中的应用 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| MX369828B (es) | 2012-05-21 | 2019-11-22 | Insmed Inc | Sistemas para tratar infecciones pulmonares. |
| EP3536787A1 (en) | 2012-06-08 | 2019-09-11 | Translate Bio, Inc. | Nuclease resistant polynucleotides and uses thereof |
| WO2013186793A1 (en) * | 2012-06-11 | 2013-12-19 | Council Of Scientific & Industrial Research | Rice bran-lipids based formulation and process for preparation thereof for selective delivery of genes to cancer cells |
| US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
| AU2013340414B2 (en) | 2012-10-23 | 2019-05-02 | Caris Science, Inc. | Aptamers and uses thereof |
| BR112015010220A2 (pt) | 2012-11-05 | 2017-12-05 | Pronai Therapeutics Inc | métodos de utilização de biomarcadores para tratamento de câncer |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| RU2018135921A (ru) | 2012-11-29 | 2019-02-05 | Инсмед Инкорпорейтед | Стабилизированные составы ванкомицина |
| EP2935628B1 (en) | 2012-12-19 | 2018-03-21 | Caris Life Sciences Switzerland Holdings GmbH | Compositions and methods for aptamer screening |
| PL3467108T3 (pl) | 2013-03-14 | 2024-09-30 | Translate Bio, Inc. | Sposoby oczyszczania informacyjnego rna |
| KR20210122917A (ko) | 2013-03-14 | 2021-10-12 | 샤이어 휴먼 지네틱 테라피즈 인크. | Cftr mrna 조성물 및 관련 방법 및 사용 |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| CN105263523A (zh) | 2013-03-15 | 2016-01-20 | 米尔纳疗法公司 | 使用微rna和egfr-tki抑制剂的联合癌症治疗 |
| CA2914685A1 (en) | 2013-06-24 | 2014-12-31 | Mirna Therapeutics, Inc. | Biomarkers of mir-34 activity |
| JP5914418B2 (ja) | 2013-06-26 | 2016-05-11 | 富士フイルム株式会社 | 脂質粒子、核酸送達キャリア、核酸送達キャリア製造用組成物、脂質粒子の製造方法及び遺伝子導入方法 |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| ES2707966T3 (es) | 2013-10-22 | 2019-04-08 | Translate Bio Inc | Terapia de ARNm para la deficiencia en síntesis de argininosuccinato |
| EA034103B1 (ru) | 2013-10-22 | 2019-12-27 | Транслейт Био, Инк. | СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК |
| WO2015153757A1 (en) | 2014-04-01 | 2015-10-08 | Mirna Therapeutics, Inc. | Microrna dosing regimens |
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| PT3134506T (pt) | 2014-04-25 | 2019-10-31 | Translate Bio Inc | Métodos de purificação de rna mensageiro |
| SMT202000516T1 (it) | 2014-05-15 | 2020-11-10 | Insmed Inc | Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari |
| JP6240570B2 (ja) | 2014-07-17 | 2017-11-29 | 富士フイルム株式会社 | 脂質粒子および核酸送達キャリア |
| WO2016125163A1 (en) | 2015-02-04 | 2016-08-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | LIPID ASSEMBLIES AND USES THEREOF AND SOME pH AND ELECTROSTATIC MODULATING LIPIDS TO BE USED IN SAID ASSEMBLIES |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| EP4286012A3 (en) | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| HRP20220652T1 (hr) | 2015-12-10 | 2022-06-24 | Modernatx, Inc. | Pripravci i postupci unosa terapijskih sredstava |
| HUE057877T2 (hu) | 2015-12-22 | 2022-06-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| EA201991747A1 (ru) | 2017-02-27 | 2020-06-04 | Транслейт Био, Инк. | НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| SMT202300097T1 (it) | 2017-03-15 | 2023-05-12 | Modernatx Inc | Composto e composizioni per il rilascio intracellulare di agenti terapeutici |
| US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
| MX2019013752A (es) | 2017-05-16 | 2020-07-20 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones. |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| CN111132753B (zh) * | 2017-09-04 | 2022-05-27 | 一丸自然美健有限公司 | pH敏感性脂质体及其制造方法 |
| WO2019048645A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE |
| TW201927288A (zh) | 2017-10-20 | 2019-07-16 | 德商拜恩迪克Ｒｎａ製藥有限公司 | 適用於治療之微脂體ｒｎａ配製物的製備及儲存 |
| WO2019118806A1 (en) | 2017-12-14 | 2019-06-20 | Solid Biosciences Inc. | Non-viral production and delivery of genes |
| EP3773505B1 (en) | 2018-03-30 | 2026-04-29 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| EP3775211B1 (en) | 2018-04-12 | 2023-04-05 | MiNA Therapeutics Limited | Sirt1-sarna compositions and methods of use |
| WO2019213398A1 (en) | 2018-05-02 | 2019-11-07 | Insmed Incorporated | Methods for the manufacture of liposomal drug formulations |
| US20190381034A1 (en) * | 2018-06-14 | 2019-12-19 | Ming Fang | Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases |
| CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| EP3843845B1 (en) | 2018-08-29 | 2026-03-11 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
| MA53650A (fr) | 2018-09-19 | 2021-07-28 | Modernatx Inc | Lipides peg et leurs utilisations |
| US12263248B2 (en) | 2018-09-19 | 2025-04-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| MX2021005969A (es) | 2018-11-21 | 2021-09-14 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado. |
| EP3953473A1 (en) | 2019-04-12 | 2022-02-16 | MiNA Therapeutics Limited | Sirt1-sarna compositions and methods of use |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| BR112022004936A2 (pt) | 2019-09-19 | 2022-06-14 | Modernatx Inc | Compostos lipídicos contendo carbonato e composições para distribuição intracelular de agentes terapêuticos |
| GB2632565B (en) | 2020-04-09 | 2025-06-04 | Verve Therapeutics Inc | Base editing of PCSK9 and methods of using same for treatment of disease |
| WO2021255262A1 (en) | 2020-06-19 | 2021-12-23 | Sylentis Sau | siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES |
| JP2023549011A (ja) | 2020-09-15 | 2023-11-22 | ヴァーヴ・セラピューティクス，インコーポレーテッド | 遺伝子編集のための脂質製剤 |
| GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
| EP4015634A1 (en) | 2020-12-15 | 2022-06-22 | Sylentis, S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of virus diseases |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| EP4314292A1 (en) | 2021-03-26 | 2024-02-07 | MiNA Therapeutics Limited | Tmem173 sarna compositions and methods of use |
| WO2023099884A1 (en) | 2021-12-01 | 2023-06-08 | Mina Therapeutics Limited | Pax6 sarna compositions and methods of use |
| GB202117758D0 (en) | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
| WO2023170435A1 (en) | 2022-03-07 | 2023-09-14 | Mina Therapeutics Limited | Il10 sarna compositions and methods of use |
| WO2024125597A1 (en) | 2022-12-14 | 2024-06-20 | Providence Therapeutics Holdings Inc. | Compositions and methods for infectious diseases |
| WO2024134199A1 (en) | 2022-12-22 | 2024-06-27 | Mina Therapeutics Limited | Chemically modified sarna compositions and methods of use |
| IL321425A (en) | 2022-12-23 | 2025-08-01 | Biontech Delivery Tech Gmbh | compound |
| IL326647A (en) | 2023-09-01 | 2026-04-01 | Novoarc Gmbh | Lipid nanoparticles with a nucleic acid charge and an ionizable lipid |
| NL2039380B1 (en) * | 2023-12-22 | 2025-11-25 | Coty Inc | Cationic micro-vesicles and functionalized exosome-like vectors for the delivery of functional agent to the skin |
| WO2026027887A2 (en) | 2024-08-02 | 2026-02-05 | Mina Therapeutics Limited | Hbg1/2-sarna compositions and methods of use |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599227A (en) * | 1983-11-07 | 1986-07-08 | Wisconsin Alumni Research Foundation | Injectable pharmaceutical preparation for the induction of multiple follicular growth |
| US4891208A (en) | 1985-04-10 | 1990-01-02 | The Liposome Company, Inc. | Steroidal liposomes |
| US5283122A (en) * | 1984-04-19 | 1994-02-01 | University Of Tennessee Research Corporation | Fused liposome and acid induced method for liposome fusion |
| ATE45744T1 (de) | 1984-07-25 | 1989-09-15 | Ciba Geigy Ag | Phosphatidylverbindungen, verfahren zu ihrer herstellung und ihre verwendung. |
| US5077211A (en) * | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US5290563A (en) * | 1989-07-27 | 1994-03-01 | Laboratoire Des Stallergenes | Method for combining a mixture of heterogeneous substances with liposomes |
| US5165994A (en) | 1990-06-05 | 1992-11-24 | University Of Delaware | Spontaneous equilbrium surfactant vesicles |
| US5302389A (en) * | 1992-08-17 | 1994-04-12 | Board Of Regents, The University Of Texas System | Method for treating UV-induced suppression of contact hypersensitivity by administration of T4 endonuclease |
| ATE209887T1 (de) * | 1993-04-02 | 2001-12-15 | Anticancer Inc | Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel |
| US5993850A (en) * | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
| US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| DE69708868T2 (de) | 1996-04-12 | 2002-07-18 | University Of Pittsburgh, Pittsburgh | Neue kationische cholesterin derivate mit zyklischen polaren gruppen |
| US6258792B1 (en) * | 1996-04-12 | 2001-07-10 | University Of Pittsburgh | Cationic cholesteryl derivatives containing cyclic polar groups |
| AU728581B2 (en) * | 1996-09-13 | 2001-01-11 | Lipoxen Limited | Liposomes |
| US7384923B2 (en) | 1999-05-14 | 2008-06-10 | Lipoxen Technologies Limited | Liposomes |
| US5962015A (en) * | 1997-05-02 | 1999-10-05 | Kobo Products S.A.R.L. | Stabilized liposomes |
| CA2289702C (en) * | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| CA2301166A1 (en) * | 1997-07-24 | 1999-02-04 | Yuan-Peng Zhang | Liposomal compositions for the delivery of nucleic acid catalysts |
| FR2766706B1 (fr) * | 1997-07-30 | 2001-05-25 | Biovector Therapeutics Sa | Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation |
| US6106858A (en) * | 1997-09-08 | 2000-08-22 | Skyepharma, Inc. | Modulation of drug loading in multivescular liposomes |
| JPH11302199A (ja) * | 1998-04-16 | 1999-11-02 | Sankyo Co Ltd | 薬物運搬体を構成するグラフト共重合体 |
| JP2000198731A (ja) * | 1998-10-29 | 2000-07-18 | Sankyo Co Ltd | 毒性の低減されたリポソ―ム |
| DE19852928C1 (de) * | 1998-11-17 | 2000-08-03 | Steffen Panzner | Strukturen in Form von Hohlkugeln |
| US6379698B1 (en) * | 1999-04-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Fusogenic lipids and vesicles |
| DE10010264A1 (de) | 2000-03-02 | 2001-09-13 | Novosom Gmbh | Stabilisierte Liposomen und Hüllstrukturen |
| DE10109897A1 (de) | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
| US7858117B2 (en) | 2002-02-21 | 2010-12-28 | Novosom Ag | Amphoteric liposomes and their use |
| KR20080082956A (ko) * | 2005-09-15 | 2008-09-12 | 노보솜 아게 | 양쪽성 리포솜의 개선 또는 양쪽성 리포솜에 관련된 개선 |
-
2001
- 2001-02-21 DE DE10109897A patent/DE10109897A1/de not_active Withdrawn
-
2002
- 2002-02-21 BR BRPI0207775A patent/BRPI0207775B1/pt not_active IP Right Cessation
- 2002-02-21 EP EP02701290A patent/EP1363601B1/de not_active Expired - Lifetime
- 2002-02-21 AU AU2002234643A patent/AU2002234643B2/en not_active Ceased
- 2002-02-21 WO PCT/EP2002/001880 patent/WO2002066012A2/de not_active Ceased
- 2002-02-21 CA CA2438116A patent/CA2438116C/en not_active Expired - Lifetime
- 2002-02-21 DE DE50210271T patent/DE50210271D1/de not_active Expired - Lifetime
- 2002-02-21 US US10/081,617 patent/US7371404B2/en not_active Expired - Lifetime
- 2002-02-21 CN CNB028052137A patent/CN1241549C/zh not_active Expired - Fee Related
- 2002-02-21 ES ES02701290T patent/ES2289079T3/es not_active Expired - Lifetime
- 2002-02-21 AT AT02701290T patent/ATE363893T1/de active
- 2002-02-21 JP JP2002565572A patent/JP2004525898A/ja active Pending
-
2006
- 2006-10-31 US US11/590,357 patent/US7780983B2/en not_active Expired - Lifetime
- 2006-10-31 US US11/590,143 patent/US20070269504A1/en not_active Abandoned
-
2010
- 2010-08-09 US US12/806,342 patent/US20110293695A1/en not_active Abandoned
- 2010-09-21 JP JP2010211089A patent/JP5480764B2/ja not_active Expired - Fee Related
-
2013
- 2013-11-18 JP JP2013237869A patent/JP2014031383A/ja active Pending
-
2014
- 2014-08-18 JP JP2014165961A patent/JP2014218520A/ja active Pending
-
2016
- 2016-01-07 JP JP2016001813A patent/JP2016104786A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014218520A5 (https=) | ||
| JP2011021026A5 (https=) | ||
| RU2017113970A (ru) | Стабильные составы липидов и липосом | |
| MX2021005482A (es) | Lípidos de 2,5-dioxopiperazina con porciones éster, tioéster, disulfuro y anhidrido intercaladas. | |
| Glaser et al. | Plasmenylethanolamine facilitates rapid membrane fusion: a stopped-flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adopt an HII phase with its ability to promote membrane fusion | |
| AU2013222179B2 (en) | Trialkyl cationic lipids and methods of use thereof | |
| JP5796113B2 (ja) | トランスフェクションエンハンサー要素を含む脂質および脂質集合体 | |
| ZA202101465B (en) | Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery | |
| JP2011528371A5 (https=) | ||
| BR112015005381A2 (pt) | composições de sabor com sabor e prazo de validade do sabor melhorados | |
| JP2016505545A5 (https=) | ||
| EP3378486A3 (en) | Stabilized antibody-containing liquid formulations | |
| JP2004525898A5 (https=) | ||
| PH12013502012A1 (en) | Nutritional compositions having alpha-hica and eicosapentaenoic acid | |
| MX2013002145A (es) | Tetranectina-apolipoproteina a-i, particulas lipidicas que la contienen y utilizacion de la misma. | |
| JP2017501990A5 (https=) | ||
| PH12012501269A1 (en) | Method for producing fatty acid-containing lipid using thioesterase variant | |
| Wang et al. | The cooperative behaviour of antimicrobial peptides in model membranes | |
| JP4978751B2 (ja) | リン脂質の製造方法 | |
| JP2010524463A5 (https=) | ||
| TW201625310A (zh) | ＣＫＡＰ５基因表現抑制ＲＮＡｉ醫藥組合物 | |
| Ishiyama et al. | The formation of helical tubular vesicles by binary monolayers containing a nickel-chelating lipid and phosphoinositides in the presence of basic polypeptides | |
| MY179184A (en) | Mixtures of chelating agents, and process for making such mixtures | |
| PH12019501416A1 (en) | Detergent composition | |
| CN115379831A (zh) | 包封小分子的纳米颗粒 |